6/9/2025

Scopolamine Transdermal System

Products Affected - Description

- Transderm Scop transdermal system, Baxter, 1.5 mg (1 mg/3 days), 10 count, NDC 10019-0553-03
- Transderm Scop transdermal system, Baxter, 1.5 mg (1 mg/3 days), 24 count, NDC 10019-0553-04
- Scopolamine transdermal system, Teva, 1.3 mg (1 mg/3 days), 4 count, NDC 00591-2258-04
- Scopolamine transdermal system, Teva, 1.3 mg (1 mg/3 days), 10 count, NDC 00591-2258-79
- Scopolamine transdermal system, Teva, 1.3 mg (1 mg/3 days), 24 count, NDC 00591-2258-23

Reason for the Shortage

- Baxter did not provide a reason for the shortage of Transderm Scop.
- Ingenus has scopolamine transdermal patches available.
- Padagis has scopolamine transdermal patches available.
- Rhodes has scopolamine transdermal patches available.
- Teva did not provide a reason for the shortage.
- Viatris has scopolamine transdermal patches available.
- Zydus has scopolamine transdermal patches available.

Available Products

- Scopolamine transdermal system, Ingenus Pharmaceuticals, 1.3 mg (1 mg/3 days), 4 count, NDC 50742-0505-04
- Scopolamine transdermal system, Ingenus Pharmaceuticals, 1.3 mg (1 mg/3 days), 10 count, NDC 50742-0505-10
- Scopolamine transdermal system, Ingenus Pharmaceuticals, 1.3 mg (1 mg/3 days), 24 count, NDC 50742-0505-24
- Scopolamine transdermal system, Mylan (Viatris), 1.3 mg (1 mg/3 days), 4 count, NDC 00378-6470-99
- Scopolamine transdermal system, Mylan (Viatris), 1.3 mg (1 mg/3 days), 10 count, NDC 00378-6470-97
- Scopolamine transdermal system, Mylan (Viatris), 1.3 mg (1 mg/3 days), 24 count, NDC 00378-6470-44
- Scopolamine transdermal system, Padagis, 1.3 mg (1 mg/3 days), 4 count, NDC 45802-0580-84
- Scopolamine transdermal system, Padagis, 1.3 mg (1 mg/3 days), 10 count, NDC 45802-0580-46
- Scopolamine transdermal system, Padagis, 1.3 mg (1 mg/3 days), 24 count, NDC 45802-0580-62
- Scopolamine transdermal system, Rhodes, 1.3 mg (1 mg/3 days), 4 count, NDC 42858-0150-40
- Scopolamine transdermal system, Rhodes, 1.3 mg (1 mg/3 days), 10 count, NDC 42858-0150-14
- Scopolamine transdermal system, Rhodes, 1.3 mg (1 mg/3 days), 24 count, NDC 42858-0150-70
- Scopolamine transdermal system, Zydus, 1.3 mg (1 mg/3 days), 4 count, NDC 70710-1846-04
- Scopolamine transdermal system, Zydus, 1.3 mg (1 mg/3 days), 10 count, NDC 70710-1846-02
- Scopolamine transdermal system, Zydus, 1.3 mg (1 mg/3 days), 24 count, NDC 70710-1846-07

Estimated Resupply Dates

- Baxter has Transderm Scop 1.3 mg patches on back order and the company cannot estimate a release date.
- Teva has scopolamine 1.3 mg patches in 4 count on back order and the company estimates a release date in early- to mid-July 2025. The 10 count and 24 count are also on back order and the company estimates a release date in late-October 2025.

Updated

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.